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1. Introduction {#jia225270-sec-0005}
===============

Incident cases of HIV in the United States declined 18% over the period of 2008 to 2014 except in key populations such as transgender women (transwomen) [1](#jia225270-bib-0001){ref-type="ref"}. The estimated HIV prevalence among transwomen in the US is 21.7% [2](#jia225270-bib-0002){ref-type="ref"}, higher than among almost all key populations at elevated risk of HIV. Prioritizing transwomen in the response to reducing HIV is important to ending the AIDS epidemic [3](#jia225270-bib-0003){ref-type="ref"}. An important pillar in the response is positive HIV care continuum indictors of effective diagnosis, treatment access and viral suppression [3](#jia225270-bib-0003){ref-type="ref"}.

Studies that assess transwomen\'s HIV care continuum indicators, specifically access to HIV care, antiretroviral therapy (ART) utilization and viral suppression are limited. The few studies we found indicated that transwomen have low HIV testing rates and low awareness of HIV status, low engagement and retention in HIV care, low medication adherence and low virologic suppression rates [4](#jia225270-bib-0004){ref-type="ref"}, [5](#jia225270-bib-0005){ref-type="ref"}, [6](#jia225270-bib-0006){ref-type="ref"}. Suboptimal HIV engagement rates were found among transwomen from Brazil and US transgender youth [7](#jia225270-bib-0007){ref-type="ref"}, [8](#jia225270-bib-0008){ref-type="ref"}. African American transwomen were found to have even poorer reported viral suppression (24.5%) [9](#jia225270-bib-0009){ref-type="ref"}. Past data from transwomen in San Francisco 2014 found an HIV prevalence of 39%, 87% accessed care, 65% were on ART and 44% were viral suppressed. [10](#jia225270-bib-0010){ref-type="ref"}.

In 2013, a multisector effort in San Francisco was initiated to make a concerted push towards eliminating HIV in the city [11](#jia225270-bib-0011){ref-type="ref"}. A study measuring changes along the HIV care continuum in San Francisco found significant improvements in time to ART initiation and viral suppression after diagnosis and more time from HIV to an AIDS diagnosis. However, data were not disaggregated by gender group [11](#jia225270-bib-0011){ref-type="ref"}. This study was conducted to characterize HIV care continuum indicators among transwomen in San Francisco in 2016 after initiation of efforts to eliminate HIV, and to identify factors associated with HIV care access, ART use and viral suppression. Results from this study can be used to inform policies and programmes to improve HIV care outcomes among this highly affected key population.

2. Methods {#jia225270-sec-0006}
==========

2.1. Study sample and recruitment process {#jia225270-sec-0007}
-----------------------------------------

We conducted a secondary analysis of HIV behavioural surveillance data collected from June 2016 to March 2017 from the Transwomen Empowered to Advance Community Health 3 (TEACH 3) study in San Francisco. Eligible participants were 18 years of age or older, lived in San Francisco and self‐identified as a gender different from that typically associated with a male sex assigned at birth (e.g. man). Respondent‐driven sampling (RDS) was used to recruit self‐identified adult transwomen residing in San Francisco. The initial 15 participants or "seeds" came from diverse backgrounds by race/ethnicity, education and HIV status. Seeds were asked to recruit up to 10 participants from their social networks who met eligibility criteria for the study. This recruitment process continued until equilibrium was reached with 318 transwomen (mean recruitment chain = 6; range 1 to 15). For every successful recruit enrolled into the study, the participant recruiter received \$20.00 up to a maximum of 10 recruits. After participants provided consent for study procedures, interviewers administered surveys with a handheld computer. All participants received \$65.00 for completing the survey, HIV and HCV testing. The Committee on Human Research at the University of California San Francisco approved the study. This analysis focused on the subset of 123 transwomen (38.7%) who laboratory‐tested reactive for HIV antibodies in the study.

2.2. Measurements {#jia225270-sec-0008}
-----------------

### 2.2.1. HIV testing {#jia225270-sec-0009}

Regardless of self‐reported HIV status, an INSTI^®^ HIV‐1/HIV‐2 Rapid Antibody Test was offered to all participants. Positive rapid antibody test results for those who did not know their status were confirmed using Determine™ HIV‐1/2 Ag/AB Rapid test. For those who self‐reported and were confirmed HIV positive with the rapid antibody test, no second test was conducted.

### 2.2.2. Sociodemographic factors {#jia225270-sec-0010}

The following demographic factors and social characteristics were used for this analysis: age (20 to 29, 30 to 39, 40 to 49, 50 to 59 and 60 to 75 years), gender identity (female, transgender female, androgynous, genderqueer, questioning or additional gender), race (Asian, African American, Native American, Native Hawaiian or Pacific Islander, White, Latina or Other), education (never attended school, grades 1 to 8, grades 9 to 11, completed high school, completed GED, AA degree, Technical degree, some college, Bachelor\'s degree or any postgraduate studies), born in the US (yes/no), housing status (unstable/stable), living as fulltime as their self‐reported gender identity (yes/no) and current hormone use (yes/no). In order to analyse the small number of participants who identify as androgynous, genderqueer, questioning or additional gender (n = 6), we included these participants under the umbrella term of "transgender." Transgender women were compared to those who identified as "female." Education was re‐coded as less than a high school degree, high school or equivalent degree, and more than high school education.

We identified descriptive population estimates of transwomen and the HIV care continuum based on race. No participants in this analysis identified as Native American. Due to small participant numbers, Native Hawaiian, Pacific Islander, Asian, White and participants who identified as multiple races were included in bivariate and multivariable analysis as Other.

### 2.2.3. Alcohol and substance use {#jia225270-sec-0011}

Consistent with the National HIV Behavioral Surveillance survey [12](#jia225270-bib-0012){ref-type="ref"}, the TEACH 3 survey assessed alcohol and substance use. For this analysis, substance use in the past 12 months (e.g. "Did you use any substances in the past 12 months?") was a dichotomous variable (yes/no). Alcohol use (e.g. "On a typical day when you drank alcohol in the past 12 months, how many drinks did you have?") was dichotomized based on criteria from the National Institute on Alcohol Abuse and Alcoholism [13](#jia225270-bib-0013){ref-type="ref"}: one episode of heavy drinking (\>4 drinks in one sitting) was considered high‐risk for alcohol abuse and other disorders, while four drinks or less was considered low‐risk.

### 2.2.4. Experiences of Discrimination Scale {#jia225270-sec-0012}

The Experiences of Discrimination Scale (EOD) was used to measure anti‐trans discrimination and racism in the following settings: school, hiring, work, getting housing, medical care, store, financial, public and police [14](#jia225270-bib-0014){ref-type="ref"}. The EOD scale was modified with an additional question regarding discrimination "while staying in a shelter, SRO, or residential treatment." For each of the aforementioned settings, the 10‐item EOD asked (yes/no) "Have you ever experienced discrimination, been prevented from doing something, or been hassled or made to feel inferior because of your gender identity or presentation, or race ethnicity or color?" Each question verifying setting‐based discrimination was followed by a question clarifying if the experienced discrimination was related to gender identity or presentation, race/ethnicity or both. Situation scores for gender identity, race and both gender identity and race were skewed and therefore dichotomized (yes/no) as in past studies [15](#jia225270-bib-0015){ref-type="ref"}. Cronbach\'s alpha was 0.76 for the present study.

### 2.2.5. Outcome variables {#jia225270-sec-0013}

We conducted bivariate analysis using RDS‐weighted logistic regression models to evaluate associations between demographics, substance use, discrimination and HIV care engagement and ART adherence and detectable or unknown viral loads. HIV care continuum outcome variables for this study assessed whether participants accessed HIV care, were currently on ART and had a detectable or unknown viral load. HIV care access and ART use were self‐reported and assessed as binary variables (yes/no). Viral load was self‐reported and categorized as undetectable, detectable or unknown. Outcomes for logistic regressions were coded in such a way that those currently in care and currently on ART were the reference group. Undetectable participants were the reference group for the viral load outcome (≤50 copies/mL). The focus on those not in HIV care, not on ART and with a detectable or unknown viral load presents a profile of transwomen most in need of interventions.

2.3. Statistical analyses {#jia225270-sec-0014}
-------------------------

The use of RDS in analyses lies in the ability to generate population estimates from the sample using various weights based on certain assumptions [16](#jia225270-bib-0016){ref-type="ref"}, [17](#jia225270-bib-0017){ref-type="ref"}. In order to accurately estimate a hidden population with a large sample fraction, Gile\'s Successive Sampling (SS) weights were assigned using the RDS Analyst [16](#jia225270-bib-0016){ref-type="ref"}, [17](#jia225270-bib-0017){ref-type="ref"}. Our study has a high sample fraction of one‐third of transwomen with lower SES [10](#jia225270-bib-0010){ref-type="ref"}, [18](#jia225270-bib-0018){ref-type="ref"}, [19](#jia225270-bib-0019){ref-type="ref"}. RDS‐weighted logistic regressions were conducted in Stata 15 (StataCorp. 2017, College Station, TX).

Descriptive statistics are provided that summarize the demographic data on transwomen living with HIV in this sample. Due to the paucity of research on the HIV care continuum among transwomen and the exploratory nature of this study, we analysed outcomes independently rather than conditional upon each other. For the outcomes of in care and on ART, analysis was conducted with binary endpoints of yes/no. Odds ratio was used to compare these two endpoints. Whereas multinomial analysis was conducted with viral load due to the three endpoints of undetectable, detectable or unknown viral load. Relative risk ratios were conducted to compare the three probabilities. Furthermore, our multivariable analyses used a model‐building algorithm to select covariates with *p *\<* *0.25 in bivariate analysis [20](#jia225270-bib-0020){ref-type="ref"}. All *p* values are two‐sided. Population estimates are reported.

3. Results {#jia225270-sec-0015}
==========

Of the 123 transwomen who laboratory‐tested reactive for HIV, 118 participants self‐reported HIV‐positive status that laboratory tests confirmed and 5 (4.1%) transwomen self‐reported a negative or unknown HIV status but laboratory‐tested positive for HIV. There were six participants who identified as androgynous, genderqueer, questioning or additional gender. These participants were analysed under the term "transgender." Demographics based on population estimates are summarized in Table [1](#jia225270-tbl-0001){ref-type="table"}. Population estimates of HIV care engagement and ART use based on race/ethnicity were lower for transwomen of colour (African American: 82.5% HIV care, 79.1% on ART; Hispanic/Latina: 82.2% HIV care, 90.9% on ART; Multiple Races: 91.6% HIV care, 87.0% on ART) than Whites (100% HIV care, 100% on ART), with Asians having the lowest HIV care engagement (74.7%), ART use (74.7%) and undetectable viral load (54.3%). Rates were lowest across all races for reported viral suppression (African American: 69.3%; Hispanic/Latina: 68.4%; White: 61.6%; Multiple Race: 54.4%). These estimates did not adjust for housing or discrimination and is solely based on race. Of transwomen living with HIV, the population estimate of those not engaged in HIV care was 14.3%, 13% for those not currently on ART, 22.2% with a self‐reported detectable viral load and 13.5% with an unknown viral load.

###### 

Socio‐demographics with RDS‐weighted estimates for transwomen living with HIV in San Francisco, 2016 to 2017 (n = 123)

  Demographics                                                   Sample % (count)   Population estimates% (95% CI)[a](#jia225270-note-0002){ref-type="fn"}
  -------------------------------------------------------------- ------------------ ------------------------------------------------------------------------
  Age                                                                               
  20 to 29 years (reference)                                     8.94 (11)          9.87 (4.13 to 15.61)
  30 to 39 years                                                 21.95 (27)         24.73 (13.41 to 36.12)
  40 to 49 years                                                 27.64 (34)         24.42 (15.13 to 33.57)
  50 to 59 years                                                 35.59 (45)         37.78 (24.79 to 50.81)
  60 to 71 years                                                 4.88 (6)           3.21 (1.05 to 5.39)
  Gender‐female identity                                                            
  Transwoman                                                     66.67 (82)         65.23 (54.09 to 76.28)
  Female                                                         33.33 (41)         34.77 (23.72 to 45.91)
  Race/ethnicity                                                                    
  Other                                                          27.64 (34)         29.98 (18.81 to 41.18)
  African American                                               34.96 (43)         29.22 (18.26 to 40.28)
  Latina                                                         37.40 (46)         40.80 (27.57 to 53.89)
  Education                                                                         
  Less than high school                                          34.15 (42)         35.92 (23.95 to 47.68)
  High school diploma                                            36.59 (45)         40.21 (29.13 to 51.50)
  More than high school                                          29.27 (36)         23.87 (15.38 to 32.35)
  Born in the US (yes)                                           72.36 (89)         72.99 (61.39 to 84.55)
  No                                                             27.64 (34)         27.01 (20.53 to 38.41)
  Unstable housing (yes)                                         64.23 (79)         70.31 (61.59 to 79.47)
  No                                                             35.77 (44)         29.69 (20.53 to 38.41)
  Full‐time female (yes)                                         32.52 (40)         33.08 (22.18 to 44.16)
  No                                                             67.48 (83)         66.92 (55.84 to 77.82)
  Hormone use (yes)                                              70.73 (87)         64.58 (53.55 to 75.47)
  No                                                             29.27 (36)         35.42 (24.53 to 46.45)
  Alcohol use in past 12 months (yes; \>4 drinks in a sitting)   8.94 (11)          4.58 (2.44 to 6.71)
  No                                                             91.06 (112)        95.42 (93.29 to 97.56)
  Substance use in past 12 months (yes)                          54.47 (67)         51.57 (39.41 to 63.48)
  No                                                             45.53 (56)         48.43 (36.52 to 60.59)
  Gender discrimination (yes)                                    72.36 (89)         66.85 (54.63 to 79.08)
  No                                                             27.64 (34)         33.15 (20.92 to 45.37)
  Race discrimination (yes)                                      18.70 (23)         14.88 (7.61 to 22.09)
  No                                                             81.30 (100)        85.12 (77.91 to 92.38)
  Gender and race discrimination (yes)                           71.54 (88)         72.66 (62.34 to 82.89)
  No                                                             28.46 (35)         27.34 (17.11 to 37.66)

RDS, respondent‐driven sampling.

Confidence Intervals computed using the Gile\'s bootstrap method from RDS Analyst.

John Wiley & Sons, Ltd

In order to characterize discrimination across race, we added a Table [2](#jia225270-tbl-0002){ref-type="table"}. We found that African American transwomen still experience more racism and a combination of racism and anti‐trans sentiment than other race/ethnicity groups.

###### 

Anti‐trans, racism and both discrimination based on race in San Francisco, 2016 to 2017 (n = 123)

  Race               Anti‐trans, %   Racism, %   Both, %
  ------------------ --------------- ----------- ---------
  Other              29.21           13.04       19.32
  African American   35.58           47.83       40.91
  Latina             38.20           39.13       39.77

John Wiley & Sons, Ltd

3.1. Correlates of not accessing HIV care {#jia225270-sec-0016}
-----------------------------------------

The population estimate of transwomen not engaged in HIV care was 14.3%. Bivariate analysis and multivariable analysis with RDS‐weighted prevalence of those who were not engaged in HIV care are shown in Table [3](#jia225270-tbl-0003){ref-type="table"}. In bivariate analyses, transwomen who reported both anti‐trans discrimination and racism in one or more setting had 6.28 times the odds of not being engaged in HIV care than those who did not report both anti‐trans discrimination and racism (95% CI: 1.37 to 28.70; *p *=* *0.018). Age, education, substance use, racism only and both anti‐trans discrimination and racism were added to the final model for those who were not engaged in HIV care. In the multivariable logistic regression model, transwomen who were 40 to 49 years had significantly lower adjusted odds ratio (aOR) of not being in HIV care compared to the 20 to 29 years old group (aOR: 0.08; 95% CI: 0.01 to 0.74; *p *=* *0.026). Those who experienced anti‐trans discrimination and racism together had 5.14 times higher odds of not being in care (95% CI: 1.07 to 24.68; *p *=* *0.041). No other significant demographic or psychosocial associations were found.

###### 

Bivariate and multivariable analysis: RDS‐weighted estimates of transwomen living with HIV not in HIV care in San Francisco, 2016 to 2017 (n = 123)

  Demographics                                     Not in HIV care Reference group = in care   
  ------------------------------------------------ ------------------------------------------- ------------------------------------------------------------
  Age (23 to 71 years)                                                                         
  20 to 29 years (reference)                       *‐*                                         ‐
  30 to 39 years                                   *1.56 (0.20 to 12.13), p = 0.668*           0.53 (0.06 to 4.72), *p *=* *0.571
  40 to 49 years                                   *0.20 (0.03 to 1.20), p = 0.078*            **0.08 (0.01 to 0.74),** ***p *** **=** *** *** **0.026**
  50 to 59 years                                   *0.35 (0.05 to 2.37), p = 0.278*            0.20 (0.02 to 2.00), *p *=* *0.166
  60 to 71 years                                   *0.52 (0.04 to 7.04), p = 0.621*            0.36 (0.02 to 6.93), *p *=* *0.492
  Gender identity                                                                              
  Female (transgender women reference)             1.02 (0.22 to 4.62), *p *=* *0.981          [a](#jia225270-note-0004){ref-type="fn"}
  Race/ethnicity                                                                               
  Other (reference)                                ‐                                           [a](#jia225270-note-0004){ref-type="fn"}
  African American                                 3.06 (0.51 to 18.21), *p *=* *0.217         
  Latina                                           3.12 (0.40 to 24.54), *p *=* *0.278         
  Education                                                                                    
  Less than high school (reference)                *‐*                                         ‐
  High school diploma                              *0.15 (0.02‐ 1.05), p = 0.056*              0.12 (0.01 to 1.10), *p *=* *0.061
  More than high school                            *0.94 (0.17‐ 5.32), p = 0.942*              0.95 (0.18 to 5.04), *p *=* *0.947
  Born in the US                                                                               
  Yes (no is reference)                            1.69 (0.36 to 8.01), *p *=* *0.506          [a](#jia225270-note-0004){ref-type="fn"}
  Unstable housing                                                                             
  Yes (no is reference)                            1.36 (0.29 to 6.35), *p *=* *0.694          [a](#jia225270-note-0004){ref-type="fn"}
  Full‐time female                                                                             
  Yes (no is reference)                            1.11 (0.24 to 5.07), *p *=* *0.889          [a](#jia225270-note-0004){ref-type="fn"}
  Hormone use                                                                                  
  Yes (no is reference)                            1.42 (0.32 to 6.36), *p *=* *0.645          [a](#jia225270-note-0004){ref-type="fn"}
  Alcohol use in past 12 months                                                                
  Yes; \>4 drinks in a sitting (no is reference)   0.97 (0.16 to 5.83), *p *=* *0.976          [a](#jia225270-note-0004){ref-type="fn"}
  Substance use in past 12 months                                                              
  Yes (no is reference)                            *2.43 (0.54 to 10.99), p = 0.245*           2.58 (0.72 to 9.23), *p *=* *0.143
  Gender discrimination                                                                        
  Yes (no is reference)                            0.42 (0.08‐ 2.19), *p *=* *0.299            [a](#jia225270-note-0004){ref-type="fn"}
  Race discrimination                                                                          
  Yes (no is reference)                            *2.72 (0.56 to 13.14), p = 0.211*           1.91 (0.32 to 11.33), *p *=* *0.474
  Gender and race discrimination                                                               
  Yes (no is reference)                            ***6.28 (1.37 to 28.70), p = 0.018***       **5.14 (1.07 to 24.68),** ***p *** **=** *** *** **0.041**

Italics: included in the multivariable model as overall *p *\<* *0.25. Bold values: statistically significant (*p *\<* *0.05). RDS, respondent‐driven sampling.

Not included in model.

John Wiley & Sons, Ltd

3.2. Correlates of not currently on ART {#jia225270-sec-0017}
---------------------------------------

Thirteen per cent of the population of transwomen living with HIV were not on ART. In Table [4](#jia225270-tbl-0004){ref-type="table"}, the bivariate analysis is presented for those currently not on ART. Transwomen who experienced both anti‐trans discrimination and racism had 5.46 times higher odds of not being on ART than those who did not report both types of discriminations (95% CI: 1.38 to 21.53; *p *=* *0.016). Model‐building criteria informed a final multivariable model that included race, education, current hormone use, substance use, racism only and both anti‐trans discrimination and racism. In the multivariable logistic regression model, transwomen who currently used hormones had significantly lower adjusted odds of *not* being on ART than those not on hormones (aOR: 0.30; 95% CI: 0.09 to 0.92; *p *=* *0.036) (Table [4](#jia225270-tbl-0004){ref-type="table"}).

###### 

Bivariate and multivariable analysis: RDS‐weighted estimates of transwomen living with HIV not on ART in San Francisco, 2016 to 2017 (n = 123)

  Demographics                                     Not on ART Reference group = On ART     
  ------------------------------------------------ --------------------------------------- -----------------------------------------------------------
  Age (23 to 71 years)                                                                     
  20 to 29 years (reference)                       ‐                                       [a](#jia225270-note-0006){ref-type="fn"}
  30 to 39 years                                   0.73 (0.12 to 4.37), *p *=* *0.729      
  40 to 49 years                                   0.52 (0.09 to 2.95), *p *=* *0.461      
  50 to 59 years                                   0.28 (0.04 to 1.78), *p *=* *0.174      
  60 to 71 years                                   1.64 (0.17 to 15.68), *p *=* *0.665     
  Gender identity                                                                          
  Female (transgender women reference)             1.61 (0.53 to 4.94), *p *=* *0.398      [a](#jia225270-note-0006){ref-type="fn"}
  Race/ethnicity                                                                           
  Other (reference)                                *‐*                                     ‐
  African American                                 *2.36 (0.53 to 10.45), p = 0.255*       2.06 (0.42 to 10.05), *p *=* *0.369
  Latina                                           *0.90 (0.19 to 4.23), p = 0.894*        0.68 (0.12 to 4.00), *p *=* *0.666
  Education                                                                                
  Less than high school (reference)                *‐*                                     ‐
  High school diploma                              *0.70 (0.20 to 2.49), p = 0.575*        0.37 (0.10 to 1.40), *p *=* *0.142
  More than high school                            *2.20 (0.60 to 8.12), p = 0.233*        2.26 (0.61 to 8.39), *p *=* *0.222
  Born in the US                                                                           
  Yes (no is reference)                            1.26 (0.34 to 4.61), *p *=* *0.730      [a](#jia225270-note-0006){ref-type="fn"}
  Unstable housing                                                                         
  Yes (no is reference)                            1.55 (0.46 to 5.19), *p *=* *0.475      [a](#jia225270-note-0006){ref-type="fn"}
  Full‐time female                                                                         
  Yes (no is reference)                            1.76 (0.57 to 5.43), *p *=* *0.319      [a](#jia225270-note-0006){ref-type="fn"}
  Hormone use                                                                              
  Yes (no is reference)                            *0.46 (0.15 to 1.41), p = 0.172*        **0.30 (0.09 to 0.92),** ***p *** **=** *** *** **0.036**
  Alcohol use in past 12 months                                                            
  Yes; \>4 drinks in a sitting (no is reference)   1.87 (0.42 to 8.22), *p *=* *0.407      [a](#jia225270-note-0006){ref-type="fn"}
  Substance in past 12 months                                                              
  Yes (no is reference)                            *2.31 (0.74 to 7.27), p = 0.150*        1.96 (0.46 to 8.36), *p *=* *0.363
  Gender discrimination                                                                    
  Yes (no is reference)                            1.31 (0.35 to 4.83), *p *=* *0.687      [a](#jia225270-note-0006){ref-type="fn"}
  Race discrimination                                                                      
  Yes (no is reference)                            *2.21 (0.63 to 7.77), p = 0.212*        1.21 (0.26 to 5.66), *p *=* *0.808
  Gender and race discrimination                                                           
  Yes (no is reference)                            ***5.46 (1.38 to 21.53), p = 0.016***   5.46 (0.93 to 32.12), *p *=* *0.060

Italics: included in the multivariable model as overall *p *\<* *0.25. Bold values: statistically significant (*p *\<* *0.05). ART, antiretroviral therapy; RDS, respondent‐driven sampling.

Not included in model.

John Wiley & Sons, Ltd

3.3. Correlates of detectable/unknown viral load {#jia225270-sec-0018}
------------------------------------------------

Of transwomen living with HIV, the population estimate of transwomen with a self‐reported detectable viral load was 22.2% and 13.5% with an unknown viral load (Table [5](#jia225270-tbl-0005){ref-type="table"}). The relative risk (RR) of 40 to 49 years old transwomen with unknown viral load was significantly lower by 0.06 than those in the 20 to 29 years old group (95% CI: 0.01 to 0.43; *p *=* *0.006). Those in the 50 to 59 years old age group with unknown viral load had a lower RR of 0.13 (95% CI: 0.02 to 0.97; *p *=* *0.046) than 20 to 29 years old group. Furthermore, those with unstable housing had a 6.42 higher RR of having a detectable viral load than those in stable housing (95% CI: 1.27 to 32.48; *p *=* *0.025). Age, housing instability and experiences of both anti‐trans discrimination and racism were included in the final model as the *p *\<* *0.25. The adjusted RR (aRR) of a detectable viral load among participants with unstable housing was 7.37 times greater than those with stable housing (95% CI: 1.07 to 50.88; *p *=* *0.043). The aRR of an unknown viral load among the 40 to 49 years old transwomen compared to the 20 to 29 years old group was 0.06 times lower (95% CI: 0.01 to 0.52; *p *=* *0.011). No other associations were found.

###### 

Bivariate and multivariable analysis: RDS‐weighted estimates of transwomen living with HIV with detectable and unknown viral load in San Francisco, 2016 to 2017 (n = 123)

  Demographics                                     Detectable and unknown viral load Reference group = undetectable viral load                                                                                                       
  ------------------------------------------------ ----------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------ -----------------------------------------------------------
  Age (23 to 71 years)                                                                                                                                                                                                               
  20 to 29 years (reference)                       *‐*                                                                           *‐*                                                                                                 
  30 to 39 years                                   *0.81 (0.08 to 8.65), p = 0.859*                                              *0.19 (0.02 to 1.62), p = 0.129*       1.12 (0.09 to 14.51), *p *=* *0.931                          0.24 (0.03 to 2.25), *p *=* *0.210
  40 to 49 years                                   *0.32 (0.03 to 3.33), p = 0.339*                                              ***0.06 (0.01 to 0.43), p = 0.006***   0.58 (0.05 to 6.60), *p *=* *0.655                           **0.06 (0.01 to 0.52),** ***p *** **=** *** *** **0.011**
  50 to 59 years                                   *1.01 (0.09 to 11.74), p = 0.993*                                             ***0.13 (0.02 to 0.97), p = 0.046***   2.05 (0.16 to 26.64), *p *=* *0.580                          0.13 (0.02 to 1.05), *p *=* *0.055
  60 to 71 years                                   *0.78 (0.03 to 17.39), p = 0.874*                                             *0.54 (0.04 to 6.75), p = 0.629*       2.68 (0.13 to 54.58), *p *=* *0.518                          0.79 (0.06 to 10.19), *p *=* *0.857
  Gender identity                                                                                                                                                                                                                    
  Female (transgender women reference)             2.62 (0.58 to 11.78), *p *=* *0.208                                           1.48 (0.47 to 4.70), *p *=* *0.501     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Race/ethnicity                                                                                                                                                                                                                     
  Other (reference)                                ‐                                                                             ‐                                      [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  African American                                 0.30 (0.06 to 1.49), *p *=* *0.138                                            0.99 (0.24 to 4.06), *p *=* *0.984                                                                  
  Latina                                           0.61 (0.11 to 3.53), *p *=* *0.580                                            0.42 (0.11 to 1.59), *p *=* *0.199                                                                  
  Education                                                                                                                                                                                                                          
  Less than high school (reference)                ‐                                                                             ‐                                      [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  High school diploma                              0.93 (0.15‐ 5.80), *p *=* *0.937                                              0.91 (0.23 to 3.53), *p *=* *0.891                                                                  
  More than high school                            0.95 (0.17‐ 5.27), *p *=* *0.951                                              1.52 (0.38 to 6.02), *p *=* *0.548                                                                  
  Born in the US                                                                                                                                                                                                                     
  Yes (no is reference)                            1.19 (0.15 to 9.19), *p *=* *0.870                                            0.83 (0.25 to 2.71), *p *=* *0.752     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Unstable housing                                                                                                                                                                                                                   
  Yes (no is reference)                            ***6.42 (1.27 to 32.48), p = 0.025***                                         *1.20 (0.38 to 3.76), p = 0.757*       **7.37 (1.07 to 50.88),** ***p *** **=** *** *** **0.043**   0.71 (0.20 to 2.53), *p *=* *0.595
  Full‐time female                                                                                                                                                                                                                   
  Yes (no is reference)                            2.99 (0.66 to 13.50), *p *=* *0.154                                           1.69 (0.53 to 5.40), *p *=* *0.371     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Hormone use                                                                                                                                                                                                                        
  Yes (no is reference)                            0.72 (0.15 to 3.50), *p *=* *0.680                                            0.46 (0.14 to 1.51), *p *=* *0.199     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Alcohol use in past 12 months                                                                                                                                                                                                      
  Yes; \>4 drinks in a sitting (no is reference)   0.58 (0.06 to 5.64), *p *=* *0.637                                            1.58 (0.34 to 7.25), *p *=* *0.553     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Substance use in past 12 months                                                                                                                                                                                                    
  Yes (no is reference)                            1.70 (0.35 to 8.34), *p *=* *0.509                                            1.19 (0.38 to 3.77), *p *=* *0.765     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Gender discrimination                                                                                                                                                                                                              
  Yes (no is reference)                            1.11 (0.19 to 6.45), *p *=* *0.904                                            0.92 (0.25 to 3.46), *p *=* *0.906     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Race discrimination                                                                                                                                                                                                                
  Yes (no is reference)                            0.50 (0.10 to 2.52), *p *=* *0.400                                            1.75 (0.49 to 6.26), *p *=* *0.385     [a](#jia225270-note-0008){ref-type="fn"}                     [a](#jia225270-note-0008){ref-type="fn"}
  Gender and race discrimination                                                                                                                                                                                                     
  Yes (no is reference)                            *4.57 (0.79 to 26.37), p = 0.088*                                             *3.44 (0.99 to 11.92), p = 0.052*      4.08 (0.70 to 23.95), *p *=* *0.118                          3.36 (0.86 to 13.19), *p *=* *0.081

Italics: included in the multivariable model as overall *p *\<* *0.25. Bold values: statistically significant (*p *\<* *0.05). aRR, adjusted RR; RDS, respondent‐driven sampling; RR, relative risk ratio, probability of event occurring in the exposed group compared to occurrence in the non‐exposed group.

Not included in model.

John Wiley & Sons, Ltd

4. Discussion {#jia225270-sec-0019}
=============

We found high rates of HIV care access and ART use among transwomen living with HIV in San Francisco, although self‐reported viral load rates were lower. Approximately 86% accessed HIV care, 87% were on ART and 64% self‐reported an undetectable viral load. Our findings on HIV care engagement and treatment use were inconsistent with other studies that previously found low HIV care continuum indicators for transwomen relative to all those in San Francisco living with HIV [4](#jia225270-bib-0004){ref-type="ref"}, [5](#jia225270-bib-0005){ref-type="ref"}, [6](#jia225270-bib-0006){ref-type="ref"}, [7](#jia225270-bib-0007){ref-type="ref"}, [8](#jia225270-bib-0008){ref-type="ref"}, [9](#jia225270-bib-0009){ref-type="ref"}, [10](#jia225270-bib-0010){ref-type="ref"}. Previous data from 2014 in San Francisco found that 65% were on ART and only 44% reported viral suppression [10](#jia225270-bib-0010){ref-type="ref"}. This study suggests a significant improvement in HIV care and treatment access for transwomen in San Francisco in the past two years. Transwomen may have benefited from the increased push for HIV elimination in San Francisco that began in 2013. Partnerships were formed between community clinics, academia and public health organizations in San Francisco to push outreach and HIV testing programmes to reach the trans community [21](#jia225270-bib-0021){ref-type="ref"}. This extra push may have complimented work already being done in San Francisco\'s long‐standing trans health clinics and health department efforts for rapid linkage to HIV care for all San Franciscans [22](#jia225270-bib-0022){ref-type="ref"}.

Barriers and facilitators to optimal HIV care that can be a focus of policies and interventions to improve transwomen\'s HIV care outcomes were also identified. We found that age, current hormone use, unstable housing and the combined experience of anti‐trans discrimination and racism were significantly associated with poor HIV care continuum outcomes. Our study\'s result on age indicates that older transwomen in their 40s are less likely to not be in care and are at less risk of having an unknown viral load compared to transwomen in their 20s. These findings may be due to successful programmes that link HIV care among older transwomen. These results highlight an opportunity to increase efforts in HIV care among young transwomen.

Cross‐sex hormone therapy was associated with higher odds of ART use among transwomen living with HIV, while unstable housing and experiences of both anti‐trans discrimination and racism were barriers to ART use and viral suppression. Our results on the protective effect of hormones are contrary to prior studies that report transwomen prioritize hormone use over ART [6](#jia225270-bib-0006){ref-type="ref"}, [23](#jia225270-bib-0023){ref-type="ref"}, [24](#jia225270-bib-0024){ref-type="ref"}. Transwomen reported limited finances, transportation concerns and fear of discrimination resulting in choosing cross‐sex hormone therapy (which induces desired feminizing features among transwomen) over HIV care [23](#jia225270-bib-0023){ref-type="ref"}, [24](#jia225270-bib-0024){ref-type="ref"}, [25](#jia225270-bib-0025){ref-type="ref"}, [26](#jia225270-bib-0026){ref-type="ref"}. However, community clinics in San Francisco offer both trans healthcare and HIV care, which may reduce the need to prioritize one type of care over another [21](#jia225270-bib-0021){ref-type="ref"}, [27](#jia225270-bib-0027){ref-type="ref"}. Our contrary findings may support the notion that models of HIV care for transwomen will benefit from integration of trans‐specific care.

Our results support past studies showing that among all people living with HIV, unstable housing is associated with a detectable viral load [27](#jia225270-bib-0027){ref-type="ref"}, [28](#jia225270-bib-0028){ref-type="ref"}, [29](#jia225270-bib-0029){ref-type="ref"}. The high prevalence of transwomen with unstable housing in our study underscores the impact of housing on this population, and may, in part, be explained by reports of housing discrimination based on gender presentation [25](#jia225270-bib-0025){ref-type="ref"}, [26](#jia225270-bib-0026){ref-type="ref"}. The loss of social and familial support, which may be due to anti‐trans discrimination may also lead to a loss of stable housing [25](#jia225270-bib-0025){ref-type="ref"}, [26](#jia225270-bib-0026){ref-type="ref"}. A recent study conducted in San Francisco found that for people living with HIV, the degree of unstable housing (from single room occupancy, staying with friends, shelter or outdoors) was associated with lower odds of viral load suppression [29](#jia225270-bib-0029){ref-type="ref"}. Policies that promote access to stable housing for transwomen may mitigate high‐risk behaviours, and for those who are living with HIV, may be a facilitator to HIV care.

Previous studies found that discrimination had a significant impact on HIV care continuum indicators for transwomen living with HIV [6](#jia225270-bib-0006){ref-type="ref"}, [24](#jia225270-bib-0024){ref-type="ref"}, [25](#jia225270-bib-0025){ref-type="ref"}, [26](#jia225270-bib-0026){ref-type="ref"}, [28](#jia225270-bib-0028){ref-type="ref"}, [29](#jia225270-bib-0029){ref-type="ref"}, [30](#jia225270-bib-0030){ref-type="ref"}, [31](#jia225270-bib-0031){ref-type="ref"}, [32](#jia225270-bib-0032){ref-type="ref"}, [33](#jia225270-bib-0033){ref-type="ref"}. Prior experiences of anti‐trans discrimination were associated with delays in HIV testing among transwomen in Brazil and Jamaica [32](#jia225270-bib-0032){ref-type="ref"}, [33](#jia225270-bib-0033){ref-type="ref"}. The effects of anti‐trans discrimination may be particularly pronounced for transwomen of colour, who also face racism and bear the largest burden of HIV in the transwomen population [23](#jia225270-bib-0023){ref-type="ref"}, [24](#jia225270-bib-0024){ref-type="ref"}, [31](#jia225270-bib-0031){ref-type="ref"}.

Our study is unique in that it allows us to compare the effects of anti‐trans discrimination, racism and the combination of these two types of discrimination on HIV care continuum indicators among transwomen. We found that when measured independently, racism and anti‐trans discrimination were not associated with poor health outcomes, but when combined, discrimination was associated with not accessing HIV care. This finding supports the intersectional framework, which suggests that race and gender identity occur simultaneously and are not independent of each other and should be measured together to capture the intersectional effects of these identities [31](#jia225270-bib-0031){ref-type="ref"}, [34](#jia225270-bib-0034){ref-type="ref"}, [35](#jia225270-bib-0035){ref-type="ref"}.

This study has limitations. The study\'s cross‐sectional design limited the study due to the conditional outcomes (on ART to have suppressed viral load), a Markov‐based analysis may lead to a better interpretation of data. Given the wide confidence intervals for housing and multiple discriminations, the results indicate that these variables need more research with larger numbers of participants to determine significance. In addition, some important associations may be missed as the sample size was not large enough to detect significance. It is important to note that relative to the size of the transwomen population in San Francisco, this is a sizeable sample. A conservative estimate of the size of the transwomen population in San Francisco is 1000 transwomen [36](#jia225270-bib-0036){ref-type="ref"}. Thus, this study sample may make up 10% population of transwomen at risk of HIV in San Francisco, speaking to the importance of this study for understanding the HIV care continuum in this population.

Furthermore, this present study was limited in the ability to analyse Native Hawaiian, Pacific Islander, Asian, White and multiple races separately, highlighting the need for future studies to focus on these communities. Additionally, the use of SS weights and transferring RDS data from RDS Analyst to STATA does not necessarily ensure accurate inference to the population at large potentially limiting the ability to control for bias [37](#jia225270-bib-0037){ref-type="ref"}. The study oversampled transwomen with lower SES in San Francisco and cannot be generalizable to all San Francisco transwomen or to transwomen living in other geographical areas. Furthermore, San Francisco\'s policies and resources may differ from other cities thereby limiting the generalizability of the results. Self‐reported findings, particularly in the EOD scale and the self‐reported viral load may be influenced by social desirability or recall bias and could inflate estimates and compromise the accuracy of findings. Given the design of the study, the self‐reported viral load could not be verified. Despite these limitations, this analysis is the first of its kind to look at HIV care continuum outcomes with structural indicators and can inform future longitudinal studies with larger samples.

5. Conclusions {#jia225270-sec-0020}
==============

Despite important barriers to health for transwomen in San Francisco, this city\'s response to HIV may provide a model for HIV treatment access and elimination in this important key population. Our analysis was restricted to within differences of transwomen living with HIV and their uptake of care, next steps for research will provide insight of the uptake of HIV prevention services between HIV‐negative transwomen and transwomen living with HIV. Studies to elucidate how transwomen\'s health needs are being addressed in San Francisco are needed. Also, efforts to improve viral load suppression are sorely needed as one‐fifth in our sample were not virally suppressed despite 100% treatment access in San Francisco. Interventions to increase viral suppression will need to address the co‐occurring effect of anti‐trans discrimination and racism inside and outside the healthcare system, including housing availability and discrimination. Without efforts to address structural barriers outside clinic walls, there may be little hope of HIV elimination in San Francisco and other cities around the world.
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